New treatments for soft tissue sarcoma and cancers linked to Agent Orange exposure
Official title: First-in-class small molecules for treatment of soft tissue sarcoma and other cancers associated with Agent Orange exposure
Funded at James J Peters VA Medical Center · NIH-10951498 · Data updated 2026-11-12
This study is working on new medicines to help people with soft tissue sarcoma and other cancers linked to Agent Orange, focusing on how certain cancer cells grow and resist treatment, with the hope of finding better ways to improve patient care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | James J Peters VA Medical Center NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | October 1, 2023 |
| Project end | September 30, 2025 |
| Funding year | 2025 |
| NIH project number | 5I21BX006263-02 |
| Project ID | NIH-10951498 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients diagnosed with soft tissue sarcoma or other cancers linked to Agent Orange exposure.
✕Less likely to help
Patients with cancers not associated with Agent Orange exposure or those with early-stage cancers may not benefit from this research.
What this research studies
This research focuses on developing first-in-class small molecules to treat soft tissue sarcoma and other cancers associated with Agent Orange exposure. It aims to target specific pathways in cancer cells that contribute to their growth and resistance to existing therapies. By investigating the roles of Hypoxia Inducible Factors (HIF) and Acyl-CoA synthetase in tumor development, the research seeks to create effective treatments that can improve patient outcomes. The approach involves both laboratory studies and potential clinical applications to address the challenges faced by patients with advanced cancers.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from cancers related to Agent Orange exposure, potentially improving survival rates.
How similar studies have gone: While targeting Acss2 and HIF-2 is a novel approach, similar strategies have shown promise in other cancer types, indicating potential for success.
Where this research is happening
-
James J Peters VA Medical Center
Bronx, United States Active
Researchers
- Principal investigator: Garcia, Joseph Anthony — James J Peters VA Medical Center
- Study coordinator: Garcia, Joseph Anthony
Related research
Other NIH-funded projects on the same topics.
-
SPORE in Soft Tissue Sarcoma: targeted therapies and biomarkers to help patients
A big research effort at a major cancer center aims to develop targeted treatments and biomarkers to improve outcomes for people with soft tissue sarcoma.
-
Ultra-steerable ultrasound therapy for soft tissue sarcoma
A new ultrasound device is being developed to non-invasively shrink or remove soft tissue sarcomas while protecting nearby nerves, blood vessels, and bones.
-
Robotic ultrasound system to non-invasively remove soft tissue sarcoma
A robotic ultrasound approach aims to precisely destroy soft tissue sarcoma tumors without open surgery for people with large or hard-to-reach tumors.
-
Boosting NK-cell therapy for soft tissue sarcoma using a dog model
This project combines an antibody that soaks up a tumor-made immune blocker with natural killer (NK) cell therapy to help dogs and, eventually, people with soft tissue sarcoma fight their tumors.
-
Targeted treatments for soft tissue sarcoma
This project is testing targeted drugs and immunotherapies for people with soft tissue sarcoma, including adults and children.
-
Enhancing cancer treatment using natural killer cells in dogs with soft tissue sarcoma
This study is looking at a new way to help treat soft tissue sarcoma in dogs by using special immune cells called natural killer cells, along with a targeted antibody, to make the treatment more effective and hopefully improve outcomes for our furry friends.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.